Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: actos + 2,800 + components  Related to the article below (Last Update: 8/4/2008)

Pas? adelante lo de atr?s
Milenio, Mexico - Aug 1, 2008
Pero los sovi?ticos no conocieron los avances tecnol?gicos de la insurgencia: bombas sofisticadas al borde del camino, as? como actos suicidas incesantes, ...
Denuncian abusos contra inmigrantes
La Opini?n, CA - Jul 29, 2008
La Comisi?n indic? que los funcionarios recibieron s?lo 2800 d?lares que fueron depositados en una cuenta bancaria y "cuyo n?mero result? ser el de un jefe ...
Reclamo mundial por los rehenes
Lanacion.com (Argentina), Argentina - Jul 19, 2008
Los colombianos realizar?n hoy marchas y conciertos masivos para pedir por la libertad de m?s de 2800 secuestrados en poder de la guerrilla, en una protesta ...
Los hoteles Maritim - Una historia de ?xito
presse-service.de (Pressemitteilung), Germany - Jul 14, 2008
La sala Maritim del hotel de Bonn puede recibir hasta 2800 personas, y en el Maritim Hotel Berlin pueden celebrarse grandes actos con hasta 5.800 asistentes ...
Source: Google News

The antidiabetic PPAR-? ligands: an update on compounds in development
T Leff, JE Reed - CURRENT MEDICINAL CHEMISTRY IMMUNOLOGY ENDOCRINE AND …, 2002 - ingentaconnect.com
... Pfizer Global Research and Development, 2800 Plymouth Road ... of the transcription factor
with components of the core ... Pioglitazone (3) (marketed as Actos) [101, 102 ...

Volatile compounds from leaves and flowers of Bituminaria bituminosa (L.) Stirt.(Fabaceae) from …
A Tava, L Pecetti, M Ricci, MA Pagnotta, L Russi - FLAVOUR AND FRAGRANCE JOURNAL, 2007 - doi.wiley.com
... The relative amount (RA) of individual components of the oil are expressed as peak
area % rela- tive to total peak area from the ... n-C 28 2800 0.1?0.3 0.3 W, N ...

[PDF] PE100 Resins for Pipe Applications -
J Scheirs, LL Bohm, JC Boot, PS Leevers - Trends in Polymer Science, 1996 - staff.ttu.ee
... a high level of branching pref- erentially in the high MW component of the ... manufacturers
can be classified into three cat- egories: (I) le.rc:.actos with a ...
-

Method of treating metabolic disorders, especially diabetes, or a disease or condition associated … -
MR Gatlin, MA Ball, RO Mannion, AA Karnachi, C … - US Patent 6,878,749, 2005 - freepatentsonline.com
... effect in a non-effective dosage of one or each of the components nateglinide and ...
monohydrochloride salt or in the form as launched under the trademark ACTOS.TM ...

" Receiving the Authorities" In Chimborazo, Ecuador: Ethnic Performance in an Evangelical Andean …
R Tolen - Journal of Latin American Anthropology, 1998 - Am Anthrop Assoc
... evento considerando la importancia de actos folkloricos en ... ridges, ranging from around
2800 to 3400 ... emerged that encompasses both rural and urban components. ...
-

Thiazolidinediones: A Comparative Review of Approved Uses -
V Sood, K Colleran, MR Burge - Diabetes Technology & Therapeutics, 2000 - liebertonline.com
... Pioglitazone (Actos ? , Takedo Pharmaceuti- cals America, Inc., Lincolnshire ... of pioglita-
zone as a component of ?triple ... amino- transferase (AST) 5 2800 U/L ...

The Year's New Drugs -
AI Graul - Drug News Perspect, 2003 - journals.prous.com
... At least one of the components of the ... ACTOplus Met combines pioglitazone hydrochloride
(Actos ? ) and metformin ... 70 mg alendronate sodium and 2800 IU vitamin D ...

G GGI IIN NNK KKG GGO OO B BBI IIL LLO OOB BBA AA???A AA I IIM MMP PPO OOR RRT TT? ??N NNC CCI IIA …
Q Aplicada - dq.fct.unl.pt
... que se conhece e data de 2800 aC Os ... Os outros components principais do extracto s?o
trilactonas terpen?ides ... v?rios produtos ? base de extr actos de Ginkgo ...
-

From a glucocentric to a lipocentric approach towards metabolic syndrome -
S Mittra, VS Bansal, PK Bhatnagar - Drug Discovery Today, 2008 - Elsevier
... validated pharmacologically with Avandia ? (rosiglitazone) and Actos ? (pioglitazone),
belonging ... target that combats even the inflammatory component of MS. ...
-

Identification of a novel mitochondrial protein (HmitoNEET?) cross-linked specifically by a … -
JR Colca, WG McDonald, DJ Waldon, JW Leone, JM … - American Journal of Physiology- Endocrinology And Metabolism, 2004 - Am Physiological Soc
... Finally, in humans, pioglitazone (Actos), a weaker activator ... set of mitochondrial
proteins, including components of complex ... of ET Lund, Pfizer, 2800 Plymouth Rd ...

Source: Google Scholar
 
 

Actos improves components of diabetic dyslipidemia

 
 
Results from the first head-to-head study demonstrated that Pioglitazone ( Actos ) improved components of diabetic dyslipidemia to a significantly greater extent than Rosiglitazone ( Avandia ).

Specifically, the results indicated that treatment with Actos lowered triglycerides increased HDL-cholesterol, and improved LDL-cholesterol particle concentration and particle size.
These differences were independent of blood glucose control and occurred without the use of a traditional lipid-lowering statin medication.

Diabetic dyslipidemia is a condition commonly found in people with type 2 diabetes and is an important risk factor for cardiovascular disease, the leading cause of death for people with type 2 diabetes.
Diabetic dyslipidemia is characterized by increased triglycerides and decreased HDL-C. People with diabetic dyslipidemia also tend to have normal levels of LDL-C, but smaller, denser LDL-C particles that are likely to contribute to cholesterol build-up in arteries.

" This study provides important insight into the relative impact of each drug on important cardiovascular risk markers," noted principal investigator Ronald B. Goldberg, of the Diabetes Research Institute at the University of Miami Miller School of Medicine.
" The results demonstrate a clear difference between Actos and Avandia on their effects on diabetic dyslipidemia, with Actos lowering triglycerides and raising HDL-C to a greater extent than Avandia."

This 24-week prospective, randomized, multicenter, double-blind clinical trial enrolled 802 people with type 2 diabetes ( treated with diet alone or oral monotherapy ) and dyslipidemia ( not treated with any lipid-lowering medications ).

Following a four-week "washout" period where patients discontinued their current diabetes medication and received a placebo, patients were randomized to receive either 30 mg of Actos once daily for 12 weeks followed by 45 mg of Actos once daily for the remainder of the study, or 4 mg of Avandia once a day for 12 weeks followed by 4 mg of Avandia twice daily for the remainder of the study.
These represent the maximally effective therapeutic doses for both medications.

" By eliminating other factors such as statins to control lipids and other medications to control blood glucose levels, we obtained a clear assessment of the blood sugar and lipid effects of both drugs," added Goldberg.

The study showed that blood glucose control, which was measured by A1C, was significantly improved in both Actis- and Avandia-treated patients with comparable changes from baseline.

At baseline, average A1C scores were 7.6 percent in the Actos group and 7.5 percent in the Avandia group. Following treatment, average A1C was reduced by 0.7 percent and 0.6 percent respectively, and mean A1C for both treatment groups was below the ADA goal of less than 7 percent.

Additionally, the study demonstrated that Actos and Avandia differed significantly in their effects on blood lipids:

- triglyceride levels decreased 12.0 percent in the Actos patients, and rose 14.9 percent in the Avandia patients ( P<0.001 ).

- HDL-C rose 14.9 percent in the Actos patients, whereas it increased 7.8 percent in the Avandia patients ( P<0.001 ).

- LDL-C particle concentration was reduced with Actos and increased with Avandia (P<0.001). LDL-C particle size increased more with ACTOS (P=0.005).

- Total cholesterol (TC ) and LDL-C increased with both drugs, but to a lesser extent with Actos. TC and LDL-C rose 15.9 and 23.3 percent, respectively, in the Avandia patients; they increased 5.7 percent and 15.7 percent, respectively, in the ACTOS patients ( TC: P<0.001; LDL-C: P=0.002 ).

Pioglitazone and Rosiglitazone are insulin sensitizers belonging to the thiazolidinedione ( TZD ) class of oral anti-diabetes medications that have been approved by the Food and Drug Administration ( FDA ) to improve blood glucose control in type 2 diabetes as an adjunct to diet and exercise.

Source: Takeda Pharmaceuticals, 2005
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page